1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Novo Nordisk A/S

Novo Nordisk A/S

NONOF
Novo Nordisk A/SUS flagOther OTC
43.25
USD
-1.04
- -
192.14BMarket Cap

Total Valuation

Novo Nordisk A/S carries a market capitalization of 187.85B, placing it among publicly traded companies globally. Its enterprise value stands at 1.15T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap187.85B
Enterprise Value1.15T

Share Statistics

Novo Nordisk A/S currently has 4.44B shares outstanding.

Shares Outstanding4.44B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Novo Nordisk A/S trades at a trailing price-to-earnings ratio of 8.42. The price-to-sales ratio is 3.13, and the price-to-book ratio stands at 4.97.

PE Ratio8.42
PS Ratio3.13
PB Ratio4.97
P/TBV Ratio14.04
P/FCF Ratio4.99
P/OCF Ratio8.67

Enterprise Valuation

On an enterprise value basis, Novo Nordisk A/S trades at an EV/EBITDA multiple of 6.77 and an EV/FCF ratio of 5.51. The EV/Sales ratio of 3.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.76 provides insight into valuation relative to core operating earnings.

EV / Sales3.51
EV / EBITDA6.77
EV / EBIT7.76
EV / FCF5.51

Financial Position

Novo Nordisk A/S maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 72.09, indicating elevated leverage, while an interest coverage ratio of 42.01 demonstrates strong ability to service its debt obligations.

Current Ratio0.79
Quick Ratio0.54
Debt / Equity72.09
Debt / EBITDA0.86
Interest Coverage42.01

Financial Efficiency

Novo Nordisk A/S posts a return on equity of 70.78 and a return on invested capital of 36.44.

Return on Equity (ROE)70.78
Return on Assets (ROA)23.27
Return on Invested Capital (ROIC)36.44
Return on Capital Employed (ROCE)41.04
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.26

Taxes

Over the trailing twelve months, Novo Nordisk A/S has paid 33.72B in income taxes, reflecting an effective tax rate of 21.66.

Income Tax33.72B
Effective Tax Rate21.66

Stock Price Statistics

Novo Nordisk A/S's stock has declined approximately -40.65263% over the past 52 weeks. The 50-day moving average sits at 40.94, while the 200-day moving average is 48.77.

Beta (5Y)N/A
52-Week Price Change-40.65263%
50-Day Moving Average40.94
200-Day Moving Average48.77
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Novo Nordisk A/S generated 327.80B in revenue and converted that into 121.96B in net income, yielding earnings per share of 27.42. EBITDA reached 170.17B, while operating income came in at 148.49B.

Revenue327.80B
Gross Profit268.30B
Operating Income148.49B
Pretax Income155.68B
Net Income121.96B
EBITDA170.17B
EBIT148.49B
Earnings Per Share (EPS)27.42

Balance Sheet

Novo Nordisk A/S holds 21.63B in cash and equivalents against 146.38B in total debt, resulting in a net debt position of 125.26B. Total book value stands at 206.87B, with working capital of -47.84B providing operational flexibility.

Cash & Cash Equivalents21.63B
Total Debt146.38B
Net Debt125.26B
Equity (Book Value)206.87B
Book Value Per Share46.55
Working Capital-47.84B

Cash Flow

Novo Nordisk A/S produced 118.46B in operating cash flow over the past twelve months. After subtracting -87.57B in capital expenditures, free cash flow totaled 30.89B - equivalent to 6.95 per share.

Operating Cash Flow118.46B
Capital Expenditures-87.57B
Free Cash Flow30.89B
FCF Per Share6.95

Margins

Novo Nordisk A/S operates with a gross margin of 81.85, reflecting its pricing power and cost economics. The operating margin of 45.30 and net profit margin of 37.20 provide insight into operational efficiency.

Gross Margin81.85
Operating Margin45.30
Pretax Margin47.49
Profit Margin37.20
EBITDA Margin51.91

Dividends & Yields

The company's payout ratio of 42.47 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share11.66
Dividend YieldN/A
Payout Ratio42.47
Shareholder Yield4.91
FCF Yield20.04

Stock Splits

Novo Nordisk A/S's most recent stock split took place on September 13, 2023 with a 1:2 split ratio.

Last Split Date9/13/2023
Split Ratio1:2

Scores

Novo Nordisk A/S posts an Altman Z-Score of 4.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.17